FIELD: medicine.
SUBSTANCE: claimed group of inventions relates to medicine, namely to neurology, and deals with application of 4-aminopyridine for improving condition in case of neurocognitive and/or neuropsychiatric disorder in patients with multiple sclerosis. For this purpose effective quantity of composition with delayed release, containing 4-aminopyridine, is introduced.
EFFECT: invention provides reduction of such cognitive disorders as attention span, impaired memory and fluency, etc in patients with multiple sclerosis.
35 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING DISTURBED INNERVATION (VERSIONS) | 2013 |
|
RU2536269C1 |
| S1P MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN | 2015 |
|
RU2715734C2 |
| METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
| NEW TREATMENT OF MULTIPLE SCLEROSIS (MS) | 2011 |
|
RU2595861C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS (VERSIONS) | 2017 |
|
RU2721282C2 |
| METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS | 2014 |
|
RU2687097C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS USING LSD1 INHIBITOR | 2017 |
|
RU2768120C2 |
| COMPOSITIONS AND METHODS ASSOCIATED THEREWITH | 2017 |
|
RU2764716C2 |
| COMPOSITION AND METHOD OF AUTOIMMUNE DISEASES TREATMENT | 2012 |
|
RU2621129C2 |
| POLYMORPHOUS FORMS OF SODIUM BENZOATE AND THEIR USE | 2017 |
|
RU2782627C2 |
